TheProfitWatch

KYTX - Kyverna Therapeutics, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
7.7 -0.65 (-8.38%) -0.02 (-0.26%) 0.0 (-0.07%) -0.08 (-1.07%) -0.2 (-2.6%) -0.34 (-4.53%) 0.0 (0.0%) -0.08 (-1.06%)

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.97
Diluted EPS:
-0.97
Basic P/E:
-7.2732
Diluted P/E:
-7.2732
RSI(14) 1m:
43.61
VWAP:
7.06
RVol:

Events

Period Kind Movement Occurred At

Related News